Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807843 | 0.84 | MEN1 (0.33) | NPC1RAB9AKMT2AALOX5 | |
| SCHEMBL4804654 | 0.80 | ACHE (0.39) | ACHERELANPC1RAB9AKMT2A | |
| SCHEMBL4810247 | 0.79 | ACHE (0.33) | ACHE | |
| SCHEMBL9650411 | 0.76 | ACHE (0.34) | ACHE | |
| SCHEMBL4805089 | 0.76 | TDP1 (0.34) | ACHENPC1RAB9AKMT2A | |
| SCHEMBL5887546 | 0.73 | DYRK1A (0.44) | ACHE | |
| SCHEMBL4801089 | 0.71 | NOTUM (0.40) | NPC1 | |
| SCHEMBL19446387 | 0.70 | ACHE (0.37) | ACHERELANPC1RAB9AKMT2A | |
| SCHEMBL4804521 | 0.69 | LMNA (0.35) | NPC1RAB9A | |
| SCHEMBL4809916 | 0.68 | MAPK1 (0.38) | NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037931-B2 | Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-02 | — | — | US | claimed |
| US-7465808-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-12-16 | — | — | US | disclosed |
| US-7037931-B2 | Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-02 | — | — | US | disclosed |
| US-20060014817-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-19 | — | — | US | disclosed |
| US-20060004195-A1 | Alpha,beta-unsaturated esters and acids by stereoselective dehydration | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-05 | — | — | US | disclosed |
| US-20050026903-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-03 | — | — | US | disclosed |
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | JONES TODD K (US) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020565-A1 | Pyrazole compound; gastrointestinal disorders; central nervous system disorders | CCKAR, CCKBR, NPY1R | ACHE 915/4885RELA 3346/4885NPC1 1831/4885 |
| US-20060014817-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GIPR | ACHE 4196/4885RELA 3376/4885NPC1 1873/4885 |
| US-20060004195-A1 | Alpha,beta-unsaturated esters and acids by stereoselective dehydration | CCKAR, CCKBR, FFAR1 | ACHE 4031/4885RELA 1656/4885NPC1 1514/4885 |
| US-20050026903-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GLP1R | ACHE 3650/4885RELA 1745/4885NPC1 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.